Novo Nordisk
1Q Revenues: DKK 65.3 billion (+22%)
1Q Earnings: DKK 25.4 billion (+28%)
Comments: Sales within Diabetes and Obesity care increased by 25% to DKK 61.0 billion, mainly driven by GLP-1 diabetes sales growth of 30% and Obesity care growing by 41% to DKK 11.0 billion. Ozempic sales were DKK 29.97 billion, up 33%. Wegovy sales were DKK 9.4 billion, up 106%. Rare disease sales decreased by 4%. In the quarter, Wegovy was approved in the U.S. for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease, and Awiqli, once-weekly insulin icodec, was recommended for EU approval.